AMD has been set up as a commercial enterprise to fund programmes of development and related research in materials nanotechnology which are judged to offer practicable, effective routes to licensed technology and know-how which in turn can be taken profitably to market through a variety of commercial arrangements.
Ardent is a collaboration between Semefab, iSLI and the SMC and has been specifically created to provide the bridge between a biotechnology idea, and a marketable product, helping biotechnology businesses to grow through innovative work in microelectromechanical systems and nanotechnology.
The company's mission is to bring research and early-stage technology to market or application where it can be used to save energy, improve operational efficiency in industrial processes, provide environmental benefits through alternative energy or cleanup technology, aid in the provision of healthcare services, or simply where it is genuinely innovative.
The company provides a wide range of R&D and prototyping services. Core facilities include molecular beam epitaxy wafer growth, electron beam lithography, nano-imprint lithography, reactive ion etching and thin film deposition.